NVCN - Neovasc Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.5181
-0.0219 (-4.06%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close 0.5400
Open 0.6200
Bid 0.5260 x 1200
Ask 0.5261 x 1300
Day's Range 0.5000 - 0.6600
52 Week Range 0.3700 - 5.0000
Volume 14,393,390
Avg. Volume 2,180,739
Market Cap 32.147M
Beta (3Y Monthly) 2.58
PE Ratio (TTM) N/A
EPS (TTM) -7.6300
Earnings Date N/A
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 1.88
Trade prices are not sourced from all markets
  • CNW Group 3 days ago

    Neovasc Announces Resolution of Last Remaining Active Litigation

    VANCOUVER , April 17, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the Company has resolved the three claims for correction of patent inventorship made by Edwards Lifesciences CardiAQ LLC ("CardiAQ") in the United States District Court for the District of Massachusetts ("the Court"). Its products include the Neovasc Reducer™ (the "Reducer"), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States , Canada and Europe .

  • PR Newswire 3 days ago

    Neovasc Announces Peer Reviewed Publication in the International Journal of Cardiology Demonstrating that the Neovasc Reducer™ Improves Diastolic Function in patients suffering from severe angina

    VANCOUVER, April 17, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the International Journal of Cardiology (the "IJC") has published a peer reviewed article demonstrating that coronary sinus ("CS") narrowing through the use of the Neovasc Reducer™ (the "Reducer") improves diastolic function and relaxation of the heart. "We are pleased to report evidence that CS narrowing may also improve diastolic function in patients with chronic refractory angina and proven myocardial ischemia.

  • Associated Press last month

    Neovasc: 4Q Earnings Snapshot

    The Richmond, British Columbia-based company said it had profit of 51 cents per share. Losses, adjusted for non-recurring gains, were 15 cents per share. The medical device company posted revenue of $523,400 ...

  • CNW Group last month

    Neovasc Announces Fourth Quarter and Fiscal Year 2018 Financial Results

    Neovasc Announces Fourth Quarter and Fiscal Year 2018 Financial Results

  • PR Newswire last month

    Neovasc Wins German Court Appeal; Announces German Court's Decision to Dismiss CardiAQ's Claim to Co-inventorship of a European Patent for Tiara™

    VANCOUVER, March 21, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the Higher Regional Court in Munich, Germany, on appeal by Neovasc, has dismissed the case in full, brought by Edwards Lifesciences CardiAQ LLC ("CardiAQ") against Neovasc in Germany. In this case, CardiAQ had originally claimed full ownership rights to one of Neovasc's European patent applications for its Tiara™ ("Tiara").

  • PR Newswire last month

    Reducer Featured in Presentation at American College of Cardiology's Annual Meeting

    VANCOUVER, March 19, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that data on the Neovasc Reducer™ ("Reducer") was featured in session 725, titled, "Refractory Angina: Options for Patients With "No Options"" at the American College of Cardiology's ("ACC") 68th Annual Scientific Session and Expo ("ACC.19"). "We are pleased that today's ACC.19 session included an overview of our Reducer and its efficiency in narrowing the coronary sinus in refractory angina patients, which has resulted in an improvement in symptoms and quality of life for patients with refractory angina who were not candidates for revascularization.  A portion of the data discussed during the session was originally published in the New England Journal of Medicine in February 20151," stated Fred Colen, CEO of Neovasc.

  • PR Newswire last month

    Neovasc Announces Closing of $5 Million Public Offering of Common Shares

    NASDAQ, TSX: NVCN VANCOUVER , March 15, 2019 /PRNewswire/ -   Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN / TSX: NVCN) announced today that it has closed its previously ...

  • PR Newswire last month

    Neovasc Completes Successful Quality System Surveillance Audit

    VANCOUVER, March 14, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that it has successfully completed its 2019 mandatory Surveillance Audit with its Notified Body, resulting in the maintenance of the Regulatory Certification (EC marking) and maintenance of the ISO 13485: 2016 certification of the quality management system.

  • PR Newswire last month

    Neovasc to Announce Year Ended December 31, 2018 Financial Results on Thursday, March 21

    Conference Call Scheduled for 4:30pm Eastern Time NASDAQ, TSX: NVCN VANCOUVER , March 13, 2019 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader ...

  • Benzinga last month

    The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 12) Elanco Animal Health Inc (NYSE: ELAN ) CareDx Inc ...

  • CNW Group last month

    Neovasc Announces Pricing of $5 Million Public Offering of Common Shares

    VANCOUVER , March 13, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN / TSX: NVCN) announced today the pricing of its previously announced underwritten public offering (the "Offering") of 11,111,111 common shares of the Company (the "Common Shares") at a price to the public of US$0 .45 per Common Share, for aggregate gross proceeds to the Company of approximately US$5 million , before deducting the underwriting commission and estimated Offering expenses payable by the Company.  The Offering is expected to close on or about March 15, 2019 , subject to customary closing conditions. H.C. Wainwright & Co. (the "Underwriter") is acting as sole book-running manager for the Offering.

  • CNW Group last month

    Neovasc Announces Proposed Public Offering of Common Shares

    Neovasc Announces Proposed Public Offering of Common Shares

  • CNW Group last month

    Neovasc Announces Agreements to Exchange Outstanding Warrants for Shares

    Neovasc Announces Agreements to Exchange Outstanding Warrants for Shares

  • PR Newswire 2 months ago

    Neovasc Announces Reducer™ Implant "Live Case" at the CRT Meeting in Washington, DC

    VANCOUVER, March 5, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that an implant procedure of the Neovasc Reducer™ ("Reducer") was featured in a "Live Case" broadcast at the Cardiovascular Research Technologies (CRT) meeting being held March 2-5, 2019 in Washington, DC. The implant procedure was performed by Dr. Francesco Giannini from the Maria Cecilia Hospital in Cotignola, Italy. Following the case there was a lot of interest from the CRT audience, including comments on the procedure and curiosity about the Reducer's mechanism of action.